Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.6K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

793
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
793
Cancer02:18

Cancer

54.8K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.8K
Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T-Cell Clonal Expansion in Peripheral Blood Following Interventional Radiology Procedures for Metastatic Liver Cancer.

Cancers·2026
Same author

Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma.

Transplantation and cellular therapy·2026
Same author

Staging of non-metastatic nasopharyngeal carcinoma with PET/CT.

European radiology·2026
Same author

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Cancer cell·2026
Same author

Human endogenous retrovirus profiling reveals heterogenous expression in cutaneous melanoma.

Frontiers in oncology·2026
Same author

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Cancer cell·2026
Same journal

Identification of a Novel <i>GOLGB1-RET</i> Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

JCO precision oncology·2026
Same journal

Cross-Platform Gene Signature to Predict Survival Outcomes for Nasopharyngeal Carcinoma.

JCO precision oncology·2026
Same journal

Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy Tissue.

JCO precision oncology·2026
Same journal

Complete Response to Immune Checkpoint Inhibitor-Based Combination Therapy in PD-L1-High, Tumor Mutational Burden-Low Ovarian Sarcomatoid Squamous Cell Carcinoma.

JCO precision oncology·2026
Same journal

Emergence of Microsatellite Instability in an Oncogene-Driven Non-Small Cell Lung Cancer Harboring a Canonical <i>EGFR</i> Mutation: A Molecular Tumor Board Discussion.

JCO precision oncology·2026
Same journal

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

JCO precision oncology·2026
See all related articles

Related Experiment Video

Updated: Feb 23, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.3K

OncoKB: A Precision Oncology Knowledge Base.

Debyani Chakravarty1, Jianjiong Gao1, Sarah M Phillips1

  • 1, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , , Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Department of R&D and Bioinformatics, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

JCO Precision Oncology
|September 12, 2017
PubMed
Summary
This summary is machine-generated.

OncoKB is a new precision oncology knowledge base that helps doctors interpret tumor mutations. It identifies actionable alterations in 41% of samples, guiding better cancer treatment decisions.

More Related Videos

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology
07:03

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology

Published on: December 1, 2023

1.5K
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.5K

Related Experiment Videos

Last Updated: Feb 23, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.3K
Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology
07:03

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology

Published on: December 1, 2023

1.5K
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.5K

Area of Science:

  • Precision oncology
  • Genomic medicine
  • Cancer genomics

Background:

  • Prospective clinical sequencing of tumors is crucial for personalized cancer care.
  • A need exists for tools to interpret the clinical significance of tumor mutations.
  • OncoKB addresses this need by providing standardized, interpretable information.

Purpose of the Study:

  • To develop OncoKB, an expert-guided knowledge base for precision oncology.
  • To annotate the biological and clinical implications of somatic molecular alterations.
  • To stratify treatment implications based on evidence levels for drug response.

Main Methods:

  • Annotated biological and oncogenic effects of somatic molecular alterations.
  • Assessed prognostic and predictive significance of these alterations.
  • Stratified treatment implications using FDA labeling, NCCN guidelines, expert recommendations, and literature.

Main Results:

  • Annotated over 3000 mutations, fusions, and copy number alterations in 418 cancer genes.
  • Analyzed 5983 tumor samples across 19 cancer types.
  • Found 41% of samples had actionable alterations, with 7.5% predicting clinical benefit from standard treatment.

Conclusions:

  • OncoKB provides comprehensive, curated, evidence-based information on tumor alterations.
  • Supports oncologists in making optimal treatment decisions for cancer patients.
  • Facilitates interpretation of genomic data for physicians and researchers.